FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum
HIKAL Share Price Target
Hikal Ltd.
Sector: Pharmaceuticals and health care
Sector: Pharmaceuticals and health care
HIKAL Share Price *
108.85 -0.05 (-0.05%)
* (quote may be delayed)
HIKAL Share Price Forecast - Consensus
| No. of reports in last year | 5 |
| No. of analysts | 2 |
| Average Consensus Forecast | 190.60 |
| Consensus Potential | 41.47% |
HIKAL Share Price Target - Broker Reports - 2019
ICICIdirect.com
30-Oct-19
Price @ Call: 117.09
Target: 140
BUY
The hitherto unblemished growth track record was impacted by certain unforeseen one-offs (flood and water cut) besides a scheduled shutdown for capacity expansion. While the management has assured on substantial recouping (if not entire) of the lost business in Q3, Q4, the lack of disclosures of these events has already taken a toll on the stock price. Coming back to earnings, the full year revenue guidance of 5-10% seems difficult. However, going by the capex guidance, things are looking promising for FY21. On the margins front, gross margins are improving due to focus on high margin products. However, the management has to improve on the disclosure front as this is one of the major sources of information for B2B players like Hikal. But for this lacuna, Hikal continues to offer a compelling value proposition as it continues to expand in both pharma and crop protection segments with separate focus and a calibrated approach. This bodes well in the current scenario when Chinese supply disturbances are likely to create opportunities for Indian players both in APIs and crop protection CDMO. We arrive at a valuation of rs 140 based on 14x FY21E EPS of Rs 11.7.
ICICIdirect.com
2-Aug-19
Price @ Call: 146.8
Target: 190
BUY
Key takeaways from Q1 numbers were strong growth in crop protection, steady growth in pharma but lower blended level margins that are attributable to a product mix and plant related expenses. The management still remains conservative on the revenue growth guidance front (10-15% in FY20 maintained) as the focus is likely to be on high margin products besides a close watch on capacities. With proven capabilities and management pedigree, we believe Hikal offers a compelling value proposition as it continues to expand in both pharma and crop protection segments with separate focus and a calibrated approach. This bodes well in the current scenario when Chinese supply disturbances are likely to create opportunities for Indian players both in APIs and crop protection CDMO. We arrive at a valuation of Rs 190 based on 14x FY21E EPS of | 13.6.
ICICIdirect.com
13-May-19
Price @ Call: 174.7
Target: 205
BUY
For years, the company has been dealing with high profile MNCs like Merck & Co, Bayer, Syngenta, BASF, Pfizer to name a few. With proven capabilities and management pedigree, we believe Hikal offers a compelling value proposition as it continues to expand in both pharma and crop protection segments with separate focus and a calibrated approach. This bodes well in the current scenario when Chinese supply disturbances are likely to create opportunities for Indian players both in APIs and crop protection CDMO. The company has spent ~| 500 crore over the last five years to augment capacities. After years of volatility in growth, Hikal has been witnessing a relatively stable growth trajectory. We arrive at a valuation of Rs 205 based on 15x FY21E EPS of Rs 13.7.
HDFC Securities
18-Apr-19
Price @ Call: 177.91
Target: 218
BUY
ICICIdirect.com
4-Mar-19
Price @ Call: 167.01
Target: 200
BUY
For years, the company has been dealing with high profile MNCs like Merck & Co, Bayer, Syngenta, BASF, Pfizer to name a few. With proven capabilities and management pedigree, we believe Hikal offers a compelling value proposition as it continues to expand in both pharma and crop protection segments with separate focus and a calibrated approach. This bodes well in the current scenario when Chinese supply disturbances are likely to create opportunities for Indian players both in APIs and crop protection CDMO. The company has spent ~| 500 crore over the last five years to augment capacities. After years of volatility in growth, Hikal has been witnessing a relatively stable growth trajectory. We expect sales, EBITDA, PAT to grow at a CAGR of 15%, 18%, 30%, respectively, in FY19-21E on the back of new launches and better operating leverage. Simultaneously, we also expect a 330 bps RoCE improvement to 17.3% through FY21. We arrive at a valuation of Rs 200 based on 15x FY21E EPS of Rs 13.3.
HIKAL Share Price Target - Broker Reports - 2018
ICICIdirect.com
12-Oct-18
Price @ Call: 160.62
Target: 190
BUY
HIKAL Share Price Target - Broker Reports - 2017
HDFC Securities
28-Apr-17
Price @ Call: 141.33
Target: 193.33
BUY